|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 8.01
|
Other Events.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
Press Release Dated July 14, 2022.
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
|
|
PDS BIOTECHNOLOGY CORPORATION
|
|
|
Date: July 14, 2022
|
By: /s/ Frank Bedu-Addo, Ph.D.
|
|
Name: Frank Bedu-Addo, Ph.D.
|
|
Title: President and Chief Executive Officer
|
• |
Animals vaccinated with PDS0202 demonstrated significantly higher antibody titers against H1 and H3 influenza strains compared to animals vaccinated without Infectimune™.
|
• |
All animals vaccinated with PDS0202 survived a lethal challenge with the H1N1 pandemic strain of influenza, compared to a ~40% survival rate in animals vaccinated with COBRA antigens only and a 0% survival
rate in untreated animals.
|
• |
Infectimune™ allowed for significant dose-sparing with effective protection demonstrated using 25-fold lower doses of the COBRA antigens in animals.
|
• |
No detectable virus was found in lungs from animals treated with PDS0202, compared to the presence of high virus titers in lungs evaluated both from animals treated only with COBRA antigens and also in the
untreated animals.
|
• |
The COBRA antigens elicit broadly reactive antibody responses to influenza, and Infectimune™ can promote antigen cross-presentation leading to higher immunogenicity with enhanced levels of antibody and T-cell responses resulting in
reduced doses of vaccine to protect against viral challenge in animals.
|
Document and Entity Information |
Jul. 14, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 14, 2022 |
Entity Registrant Name | PDS BIOTECHNOLOGY CORPORATION |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-37568 |
Entity Tax Identification Number | 26-4231384 |
Entity Address, Address Line One | 25B Vreeland Road |
Entity Address, Address Line Two | Suite 300 |
Entity Address, City or Town | Florham Park |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07932 |
City Area Code | 800 |
Local Phone Number | 208-3343 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001472091 |
Title of 12(b) Security | Common Stock, par value $0.00033 per share |
Trading Symbol | PDSB |
Security Exchange Name | NASDAQ |
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end
J*YE=62O:+ VS L*]:3+AK\Z/0#^TJ)?F##8#EP'Z\_ F&W*^[P]&&B>![_?E,YFIO]"O,>IM?,L/CMR&%
MIBU^:;1F%7*_SG@)M2AUVE0Q+!L\,NN";V#2&JII!-V'4^([WT8KE"VQXV1\
M'<1:I"8$'K<>J7@N5M.#9OJY';G3L%2J*W%!_NOYSB*_R7_5_OP?4$L! A0#
M% @ J4#N5)\/;$$9$P VW4 !, ( ! &)R:&,Q
M,# S.38S.5\X:RYH=&U02P$"% ,4 " "I0.Y4 93PCF05 ",80 %P
M @ %*$P 8G)H8S$P,#,Y-C,Y7V5X.3DM,2YH=&U02P$"% ,4
M " "I0.Y4XRC">U8# !Y#P $0 @ 'C* <&1S8BTR
M,#(R,#H 7(8BR".BA?P*6?OK!
M-C7M';H.B\NB'SP
M-I%U;NK"KF,?4*?",T&<)^R>_